Inactive Instrument

Highlights Celsion Corporation Nasdaq

Equities

US15117N4043

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 18	Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine	MT
Apr. 18	Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine	Apr. 18	DJ
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101	Apr. 18	CI
Top Midday Gainers	Mar. 28	MT
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Imunon, Inc. Files Ind Application to Begin Human Testing of Imnn-101	Mar. 13	CI
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer	Nov. 14	CI
IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer	23-10-18	CI
Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv	23-08-07	CI
Imunon Opening New Manufacturing Facility in Alabama to Support Production of Vaccine Formulation Components	23-06-27	MT
IMUNON, Inc. Unveils New Manufacturing Capabilities at Huntsville's HudsonAlpha Biotech Campus	23-06-27	CI
Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN 001 in Combination with Avastin in Advanced Ovarian Cancer	23-02-27	CI
Imunon, Inc. Enters into Collaborative Research Agreement with the Wistar Institute’S Vaccine & Immunotherapy Center	23-01-05	CI
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System	22-11-10	CI
Imunon, Inc. Reports Partial Results from Ongoing Non-Human Primate Study	22-10-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Celsion Corporation Nasdaq

Equities

US15117N4043

Highlights

Filters